Evaluation of the Protective Effect of Beta Glucan on Amikacin Ototoxicity Using Distortion Product Otoacoustic Emission Measurements in Rats

Basit Öğe Kaydı
dc.authoridBayindir, Tuba/0000-0003-4150-5016
dc.authoridTAN, MEHMET/0000-0001-8557-0886
dc.authorwosidKALCIOGLU, Mahmut Tayyar/I-5884-2013
dc.authorwosidBayindir, Tuba/ABG-9517-2020
dc.authorwosidKalcioglu, M. Tayyar/JAC-1515-2023
dc.authorwosidTAN, MEHMET/ABI-7574-2020
dc.contributor.authorBayindir, Tuba
dc.contributor.authorFiliz, Aliye
dc.contributor.authorIraz, Mustafa
dc.contributor.authorKaya, Serdar
dc.contributor.authorTan, Mehmet
dc.contributor.authorKalcioglu, Mahmut Tayyar
dc.date.accessioned2024-08-04T20:58:46Z
dc.date.available2024-08-04T20:58:46Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives. This experimental study investigated the possible protective effect of beta glucans on amikacin ototoxicity. Methods. Thirty-eight rats with normal distortion product otoacoustic emissions (DPOAEs) were divided into four groups. Group K was the control group. Group A was injected intramuscularly (i.m.) with amikacin 600 mg/kg/day between days 1-15. Group AB was given beta glucan gavage 1 mg/kg/day on days 0-15 and given amikacin 600 mg/kg/day i.m. on days 1-15. Group B was administered only beta glucan gavage, 1 mg/kg/day, on days 0-15.The DPOAEs were elicited in different frequency regions between 2,003 and 9,515 Hz, as distortion product diagrams (DPgrams), before and after the medication was administered, in all groups, on days 1, 5, 10, and 15. Results. No significant changes in the DPgrams were observed in group K. In group A, significant deterioration was observed at the 8,003 and 9,515 Hz frequencies on day 10, and at the 3,991, 4,557, 5,660, 6,726, 8,003, and 9,515 Hz frequencies on day 15. For group AB, statistically significant deterioration was observed at the 2,824, 8,003, and 9,515 Hz frequencies on day 15. The results for group B showed a significant improvement of hearing at the 2,378, 2,824, 3,363, and 3,991 Hz frequencies on day 1, at the 3,363, 3,991, and 8,003 Hz frequencies on day 10, and at the 8,003 Hz frequency on day 15. Conclusion. This study suggests that amikacin-induced hearing loss in rats may be limited to some extent by concomitant use of beta glucan.en_US
dc.identifier.doi10.3342/ceo.2013.6.1.1
dc.identifier.endpage6en_US
dc.identifier.issn1976-8710
dc.identifier.issn2005-0720
dc.identifier.issue1en_US
dc.identifier.pmid23525870en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.3342/ceo.2013.6.1.1
dc.identifier.urihttps://hdl.handle.net/11616/103147
dc.identifier.volume6en_US
dc.identifier.wosWOS:000317157200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKorean Soc Otorhinolaryngolen_US
dc.relation.ispartofClinical and Experimental Otorhinolaryngologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBeta glucanen_US
dc.subjectAmikacinen_US
dc.subjectOtoacoustic emission measurementen_US
dc.titleEvaluation of the Protective Effect of Beta Glucan on Amikacin Ototoxicity Using Distortion Product Otoacoustic Emission Measurements in Ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu